Warren Mason

List of Publications by Year
in descending order

36 papers	14,113 citations	257101 24 h-index	360668 35 g-index
36 all docs	36 docs citations	36 times ranked	15347 citing authors

#	Article	IF	Citations
1	MGMTGene Silencing and Benefit from Temozolomide in Glioblastoma. New England Journal of Medicine, 2005, 352, 997-1003.	13.9	6,573
2	Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Annals of Neurology, 2007, 61, 25-36.	2.8	2,166
3	Bevacizumab plus Radiotherapyâ€“Temozolomide for Newly Diagnosed Glioblastoma. New England Journal of Medicine, 2014, 370, 709-722.	13.9	2,078
4	Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma. Annals of Neurology, 2005, 58, 594-604.	2.8	516
5	Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma. Journal of Clinical Oncology, 2013, 31, 3212-3218.	0.8	489
6	Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma. Journal of Clinical Oncology, 2010, 28, 1168-1174.	0.8	450
7	Radiotherapy and Temozolomide for Newly Diagnosed Glioblastoma: Recursive Partitioning Analysis of the EORTC 26981/22981-NCIC CE3 Phase III Randomized Trial. Journal of Clinical Oncology, 2006, 24, 2563-2569.	0.8	447
8	Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial. Journal of Clinical Oncology, 2015, 33, 2735-2744.	0.8	244
9	A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation. Cancer Chemotherapy and Pharmacology, 2010, 65, 353-361.	1.1	172
10	Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma. Neuro-Oncology, 2017, 19, 1542-1552.	0.6	130
11	Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma. Neuro-Oncology, 2014, 17, 430-9.	0.6	108
12	Emerging Biomarkers in Glioblastoma. Cancers, 2013, 5, 1103-1119.	1.7	80
13	Neutrophilâ€“lymphocyte ratio dynamics during concurrent chemo-radiotherapy for glioblastoma is an independent predictor for overall survival. Journal of Neuro-Oncology, 2017, 132, 463-471.	1.4	78
14	Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma. Neuro-Oncology, 2016, 18, 1434-1441.	0.6	68
15	Impact of glycemia on survival of glioblastoma patients treated with radiation and temozolomide. Journal of Neuro-Oncology, 2015, 124, 119-126.	1.4	67
16	A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma. Oncologist, 2019, 24, 521-528.	1.9	47
17	Reversible Paraneoplastic Encephalomyelitis Associated with a Benign Ovarian Teratoma. Canadian Journal of Neurological Sciences, 1999, 26, 317-320.	0.3	42
18	Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio. Neuro-Oncology, 2016, 18, 1313-1318.	0.6	39

#	Article	IF	Citations
19	Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy. Neuro-Oncology, 2016, 18, 991-1001.	0.6	38
20	Prospective Quantification of CSF Biomarkers in Antibody-Mediated Encephalitis. Neurology, 2021, 96, e2546-e2557.	1.5	38
21	Brain Malignancy Steering Committee clinical trials planning workshop: Report from the Targeted Therapies Working Group. Neuro-Oncology, 2015, 17, 180-188.	0.6	28
22	ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenografts. PLoS ONE, 2018, 13, e0202860.	1.1	28
23	Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study. Acta Neuropathologica Communications, 2022, 10, 1.	2.4	28
24	A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study. Investigational New Drugs, 2020, 38, 1137-1144.	1.2	26
25	Progression-free survival (PFS) and health-related quality of life (HRQoL) in AVAglio, a phase III study of bevacizumab (Bv), temozolomide (T), and radiotherapy (RT) in newly diagnosed glioblastoma (GBM).. Journal of Clinical Oncology, 2013, 31, 2005-2005.	0.8	26
26	Temozolomide: The evidence for its therapeutic efficacy in malignant astrocytomas. Core Evidence, 2009, 4, 93.	4.7	25
27	Can bevacizumab prolong survival for glioblastoma patients through multiple lines of therapy?. Future Oncology, 2014, 10, 1137-1145.	1.1	16
28	Neurosurgical management of adult diffuse low grade gliomas in Canada: a multi-center survey. Journal of Neuro-Oncology, 2016, 126, 137-149.	1.4	16
29	Marizomib alone or in combination with bevacizumab in patients with recurrent glioblastoma: Phase I/II clinical trial data. Neuro-Oncology Advances, 2021, 3, vdab142.	0.4	15
30	Oculoleptomeningeal Amyloidosis Secondary to the Rare Transthyretin c.381T>G (p.Ile127Met) Mutation. World Neurosurgery, 2018, 111, 190-193.	0.7	14
31	Management and Outcomes in the Oldest-Old Population with Glioblastoma. Canadian Journal of Neurological Sciences, 2018, 45, 199-205.	0.3	10
32	Molecular Classification of Diffuse Gliomas. Canadian Journal of Neurological Sciences, 2020, 47, 464-473.	0.3	5
33	What are the prospects for combination therapy for glioblastoma?. Expert Review of Neurotherapeutics, 2017, 17, 947-949.	1.4	3
34	NANO, a practical scale for neurologic assessments in patients with brain tumors?. Neuro-Oncology, 2017, 19, 603-604.	0.6	2
35	Reply to T.J. Kruser et al. Journal of Clinical Oncology, 2016, 34, 1282-1283.	0.8	1
36	Malignant Gliomas: Present and Future Therapeutic Drugs. , 2011, , 207-214.		0